Dublin, Jan. 30, 2023 (GLOBE NEWSWIRE) -- The "HIV/AIDS Diagnostics Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030" report has been added to ResearchAndMarkets.com's offering.
This report offers strategic insights into the overall HIV/AIDS diagnostics market along with the market size and estimates.. The said research study covers in-depth analysis of multiple market segments based on type of product and different geographies. The product type segment studied for analyzing the overall global HIV/AIDS diagnostics market is majorly segmented into antibody test, HIV-2 & Group O diagnostic Tests, viral load tests, CD4 testing, early infant diagnostics, viral identification testing.
According to WHO study, until now around 70 million people are infected with HIV virus and 35 million died of HIV infection. With rising mortality, the government and non-government institutes are taking initiatives and providing funding for diagnostic treatment and prevention of HIV/AIDS.
With advancement of technology, novel diagnostic product are available in market which required minimum technical skills such as portable cell counter and point of care rapid diagnostic tests that fasten the diagnosis process. In developing countries such as India and China with growing population, rising awareness about HIV and emerging economies will be lucrative market for HIV/AIDS diagnostics. Increase in incidence of HIV infection, awareness about HIV/AIDs diagnosis and treatment, rising research and development for early diagnosis, treatment and prevention are key the factors driving the HIV/AIDS diagnostic market.
Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global HIV/AIDS diagnostics market.
Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global HIV/AIDS diagnostics market. This report concludes with company profiles section that highlights major information about the key players engaged in global HIV/AIDS diagnostics market. In-depth competitive environment analysis and historical (2020) market size data are also provided in the report.
HIV/AIDS diagnostics market based on the type of products:
The most widely used test for detection of the HIV infection is antibody testing. Technological advancement in screening tests, rising incidence of HIV and growing awareness about blood donation, act as the major drivers of the antibody testing market. Rapid tests and ELISA form the major markets for the HIV diagnostic tests.
With advances in technology, antibody confirmatory have become extremely accurate in giving end result, for example western blot test delivers 100% accuracy result screening post antibody test. Thus owing to high accuracy rate and increase in usage, antibody tests will continue to occupy dominant position in the forecast period. Monitoring tests such as viral load test, and CD4 testing are used to evaluate virologic load and assessment of the treatment safety, are anticipated to be the fastest growing market.
In 2021, North America dominated the global HIV/AIDS diagnostics market followed by the Europe. In North America region, U.S. occupies the maximum share of the market due to rise in prevalence of HIV infection, growing awareness programs and health care access, national funding for HIV affected people. Canada at regional level has different programs laid for treatment of AIDS, which further drives the diagnostic market in the country.
Europe is the next important market driven by factors such as convenient access to health care facilities, high healthcare spending and introduction of novel treatment opportunities. Asia Pacific is anticipated to be fastest growing in HIV/AIDS diagnostic market in the forecast period. Developing countries contribute to rising number of HIV-AIDS population, and along with increase in government initiative for HIV diagnostic and treatment facilities, rising healthcare expenditure further drives the diagnostic market for Asia pacific.
Historical & Forecast Period
This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.
Key questions answered in this report
- What are the key micro and macro environmental factors that are impacting the growth of HIV/AIDS Diagnostics market?
- What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
- Estimated forecast and market projections up to 2030.
- Which segment accounts for the fastest CAGR during the forecast period?
- Which market segment holds a larger market share and why?
- Are low and middle-income economies investing in the HIV/AIDS Diagnostics market?
- Which is the largest regional market for HIV/AIDS Diagnostics market?
- What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
- Which are the key trends driving HIV/AIDS Diagnostics market growth?
- Who are the key competitors and what are their key strategies to enhance their market presence in the HIV/AIDS Diagnostics market worldwide?
Key Topics Covered:
1. Preface
2. Executive Summary
3. HIV/AIDS Diagnostics Market: Competitive Analysis
3.1. Market Positioning of Key HIV/AIDS Diagnostics Market Vendors
3.2. Strategies Adopted by HIV/AIDS Diagnostics Market Vendors
3.3. Key Industry Strategies
3.4. Tier Analysis 2021 Versus 2030
4. HIV/AIDS Diagnostics Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global HIV/AIDS Diagnostics Market Value, 2020 - 2030, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
5. HIV/AIDS Diagnostics Market: By Product, 2020-2030, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2021 Versus 2030
5.3. Market Segmentation
5.3.1. Antibody Tests
5.3.1.1. HIV-1 Screening Tests
5.3.1.2. ELISA
5.3.1.3. Rapid Tests
5.3.1.4. Home Access Dried Blood Spots
5.3.2. HIV-1 Antibody Confirmatory Tests
5.3.2.1. Western Blot Tests
5.3.2.2. Indirect Immunofluorescence Assays (IFA)
5.3.2.3. Line Immunoassays
5.3.2.4. Radio-Immunoprecipitation Assays
5.3.3. Viral Identification testing
5.3.3.1. P24 Antigen
5.3.3.2. Qualitative PCR Test
5.3.3.3. Viral Culture
5.3.4. Viral Load Tests
5.3.5. CD4 Testing
5.3.6. Early Infant Diagnostics
6. North America HIV/AIDS Diagnostics Market, 2020-2030, USD (Million)
7. UK and European Union HIV/AIDS Diagnostics Market, 2020-2030, USD (Million)
8. Asia Pacific HIV/AIDS Diagnostics Market, 2020-2030, USD (Million)
9. Latin America HIV/AIDS Diagnostics Market, 2020-2030, USD (Million)
10. Middle East and Africa HIV/AIDS Diagnostics Market, 2020-2030, USD (Million)
11. Company Profile
11.1. Abbott Laboratories
11.1.1. Company Overview
11.1.2. Financial Performance
11.1.3. Product Portfolio
11.1.4. Strategic Initiatives
11.2. Abbvie Inc.
11.2.1. Company Overview
11.2.2. Financial Performance
11.2.3. Product Portfolio
11.2.4. Strategic Initiatives
11.3. Alere Inc.
11.3.1. Company Overview
11.3.2. Financial Performance
11.3.3. Product Portfolio
11.3.4. Strategic Initiatives
11.4. Apogee Flow Systems
11.4.1. Company Overview
11.4.2. Financial Performance
11.4.3. Product Portfolio
11.4.4. Strategic Initiatives
11.5. Beckman Coulter, Inc.
11.5.1. Company Overview
11.5.2. Financial Performance
11.5.3. Product Portfolio
11.5.4. Strategic Initiatives
11.6. Becton, Dickinson & Company
11.6.1. Company Overview
11.6.2. Financial Performance
11.6.3. Product Portfolio
11.6.4. Strategic Initiatives
11.7. BD Biosciences
11.7.1. Company Overview
11.7.2. Financial Performance
11.7.3. Product Portfolio
11.7.4. Strategic Initiatives
11.8. Bio-Rad Laboratories
11.8.1. Company Overview
11.8.2. Financial Performance
11.8.3. Product Portfolio
11.8.4. Strategic Initiatives
11.9. BioMerieux
11.9.1. Company Overview
11.9.2. Financial Performance
11.9.3. Product Portfolio
11.9.4. Strategic Initiatives
11.10. Bristol-Myers Squibb
11.10.1. Company Overview
11.10.2. Financial Performance
11.10.3. Product Portfolio
11.10.4. Strategic Initiatives
11.11. Cepheid
11.11.1. Company Overview
11.11.2. Financial Performance
11.11.3. Product Portfolio
11.11.4. Strategic Initiatives
11.12. Chembio Diagnostics Systems
11.12.1. Company Overview
11.12.2. Financial Performance
11.12.3. Product Portfolio
11.12.4. Strategic Initiatives
11.13. Daktari Diagnosticss
11.13.1. Company Overview
11.13.2. Financial Performance
11.13.3. Product Portfolio
11.13.4. Strategic Initiatives
11.14. Gilead Sciences
11.14.1. Company Overview
11.14.2. Financial Performance
11.14.3. Product Portfolio
11.14.4. Strategic Initiatives
11.15. Hologic Inc.
11.15.1. Company Overview
11.15.2. Financial Performance
11.15.3. Product Portfolio
11.15.4. Strategic Initiatives
11.16. Merch & Co. Inc
11.16.1. Company Overview
11.16.2. Financial Performance
11.16.3. Product Portfolio
11.16.4. Strategic Initiatives
11.17. Mylan Inc
11.17.1. Company Overview
11.17.2. Financial Performance
11.17.3. Product Portfolio
11.17.4. Strategic Initiatives
11.18. Janssen Therapeutics
11.18.1. Company Overview
11.18.2. Financial Performance
11.18.3. Product Portfolio
11.18.4. Strategic Initiatives
For more information about this report visit https://www.researchandmarkets.com/r/52wiqn
